Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alon...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241311379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560347140423680 |
|---|---|
| author | Yue Qiu Yaqin Shi Zhujun Chao Xinyu Zhu Yan Chen Linlin Lu |
| author_facet | Yue Qiu Yaqin Shi Zhujun Chao Xinyu Zhu Yan Chen Linlin Lu |
| author_sort | Yue Qiu |
| collection | DOAJ |
| description | Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers. |
| format | Article |
| id | doaj-art-8a0518decd83476f88f01f261da1c6ee |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-8a0518decd83476f88f01f261da1c6ee2025-01-04T08:03:28ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-01-011710.1177/17588359241311379Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 statusYue QiuYaqin ShiZhujun ChaoXinyu ZhuYan ChenLinlin LuDespite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers. In response to this gap, antibody-drug conjugates (ADCs) have emerged as a promising approach. ADCs combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy, which allows for the targeted delivery of a cytotoxic payload to cancer cells. ADCs have been used as adjuvant chemotherapeutic treatments and salvage therapies across various breast cancer subtypes, which have greatly improved the prognosis of breast cancer patients. Numerous ongoing clinical trials seek to optimize dosing strategies and identify patient populations that would benefit most from ADCs. This review presents an updated and comprehensive overview of emerging investigational ADCs for treating breast cancer patients with various HER2 subtypes. These ADCs are spearheading a new era in targeted cancer therapy, promising to innovate treatment paradigms for both HER2-positive and HER2-low breast cancers.https://doi.org/10.1177/17588359241311379 |
| spellingShingle | Yue Qiu Yaqin Shi Zhujun Chao Xinyu Zhu Yan Chen Linlin Lu Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status Therapeutic Advances in Medical Oncology |
| title | Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status |
| title_full | Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status |
| title_fullStr | Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status |
| title_full_unstemmed | Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status |
| title_short | Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status |
| title_sort | recent advances of antibody drug conjugates in treating breast cancer with different her2 status |
| url | https://doi.org/10.1177/17588359241311379 |
| work_keys_str_mv | AT yueqiu recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status AT yaqinshi recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status AT zhujunchao recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status AT xinyuzhu recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status AT yanchen recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status AT linlinlu recentadvancesofantibodydrugconjugatesintreatingbreastcancerwithdifferenther2status |